An atlas of altered expression of deubiquitinating enzymes in human cancer by C. Luise et al.
An Atlas of Altered Expression of Deubiquitinating
Enzymes in Human Cancer
Chiara Luise1, Maria Capra1, Maddalena Donzelli2, Giovanni Mazzarol2, Maria Giovanna Jodice1, Paolo
Nuciforo1, Giuseppe Viale2,3, Pier Paolo Di Fiore1,2,3*, Stefano Confalonieri1*
1 IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy, 2 Istituto Europeo di Oncologia, Milan, Italy, 3Dipartimento di Medicina, Chirurgia e Odontoiatria,
Universita` degli Studi di Milano, Milan, Italy
Abstract
Background: Deubiquitinating enzymes (DUBs) are proteases that process ubiquitin (Ub) or ubiquitin-like gene products,
remodel polyubiquitin(-like) chains on target proteins, and counteract protein ubiquitination exerted by E3 ubiquitin-
ligases. A wealth of studies has established the relevance of DUBs to the control of physiological processes whose
subversion is known to cause cellular transformation, including cell cycle progression, DNA repair, endocytosis and signal
transduction. Altered expression of DUBs might, therefore, subvert both the proteolytic and signaling functions of the Ub
system.
Methodology/Principal Findings: In this study, we report the first comprehensive screening of DUB dysregulation in human
cancers by in situ hybridization on tissue microarrays (ISH-TMA). ISH-TMA has proven to be a reliable methodology to
conduct this kind of study, particularly because it allows the precise identification of the cellular origin of the signals. Thus,
signals associated with the tumor component can be distinguished from those associated with the tumor
microenvironment. Specimens derived from various normal and malignant tumor tissues were analyzed, and the ‘‘normal’’
samples were derived, whenever possible, from the same patients from whom tumors were obtained. Of the ,90 DUBs
encoded by the human genome, 33 were found to be expressed in at least one of the analyzed tissues, of which 22 were
altered in cancers. Selected DUBs were subjected to further validation, by analyzing their expression in large cohorts of
tumor samples. This analysis unveiled significant correlations between DUB expression and relevant clinical and
pathological parameters, which were in some cases indicative of aggressive disease.
Conclusions/Significance: The results presented here demonstrate that DUB dysregulation is a frequent event in cancer,
and have implications for therapeutic approaches based on DUB inhibition.
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Introduction
The post-translational modification of proteins by mono- or
poly-ubiquitination is critical for the regulation of protein stability,
activity and interactions. Through the modulation of these target
protein properties, ubiquitination controls several cellular pro-
grams, including signal transduction, vesicular transport, tran-
scription, apoptosis, chromatin remodeling, and DNA repair
[1–7]. Similar to other covalent modifications, such as phosphor-
ylation or methylation, ubiquitination is reversible. Approximately
100 deubiquitinating enzymes (DUBs) are encoded by the human
genome, of which 90 appear to be expressed [8]. These enzymes
cleave the isopeptide linkage between the protein substrate and the
ubiquitin (Ub) residue, thereby terminating Ub-dependent signal-
ing. DUBs belong to the superfamily of peptidases, specifically to
the cysteine- and metallo-peptidase families. On the basis of their
Ub-protease domain, the cysteine-peptidase DUBs may be further
organized into four subclasses: Ub carboxyl-terminal hydrolases,
families 1 (UCH) and 2 (USP) [9], ovarian tumor-like (OTU or
OTUBIAN) proteases [10,11], and the Machado-Joseph disease
(MJD or MACHADO) proteases [12]. In addition, one class of
DUB metallo-enzymes has been described: the JAB1/MPN/
Mov34 (JAMM) family [13].
DUBs participate in the regulation of several biological
functions. Some DUBs have been found in complex with the
proteasome, where their function is required for protein
degradation and Ub recycling [14,15]. In other cases, DUBs are
involved in remodeling the Ub content of target proteins, a
mechanism referred to as Ub-editing. This process might be
involved in the rescuing of erroneously ubiquitinated proteins from
proteasomal degradation, or in the fine modulation of the amount
and type of Ub chains linked to particular substrates [16]. Finally,
and not surprisingly given the vast involvement of the Ub system
in intracellular signaling, virtually every aspect of cell regulation is
intersected by DUBs, including regulation of transcription,
chromatin remodeling, intracellular vesicular trafficking, DNA
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repair, cell cycle progression, apoptosis, and signal transduction
kinase cascades (for recent reviews see [17,18]).
Subversion of DUBs might, therefore, alter both the proteolytic
and signaling functions of the Ub system. This is predicted to affect
cellular homeostasis and, in certain circumstances, to promote
cellular transformation. Indeed, both oncogenic and tumor
suppressor roles have been proposed for a number of DUBs
[18,19], leading to the concept that they might represent attractive
targets for novel cancer therapies ([20,21] and references therein).
Thus, a better understanding of the functional roles of DUBs in
cancer might have important consequences for cancer treatment,
especially in light of recent advances in the development of DUB-
specific small molecule inhibitors [22]. However, understanding
the exact role of DUBs in ‘‘real’’ cancers is complicated by the fact
that DUBs have multiple substrates. Thus, an atlas of DUB
alterations in human cancer might provide an important tool to
direct future pharmacological developments. At the genetic level,
mutations or rearrangements/translocations of DUBs seem rare
(with the important caveat that the issue has not been extensively
investigated). Conversely, alterations in the levels of expression
appear to be more frequent (for recent reviews of cancer-related
DUBs, see [18,19]). Here, we report the first comprehensive
screening of alterations in DUB expression in nine human cancers.
This study represents the first step towards the compilation of a
systematic catalog of DUB dysregulation in cancer.
Results
Study design
A schematic of the study design is depicted in Figure 1A. A total
of 89 DUB-encoding genes were analyzed by in situ hybridization
(ISH) on multi-tumor tissue microarrays (TMAs). We employed
ISH/TMA as the screening platform because, among RNA based
technologies, ISH/TMA couples the advantages of a medium/
high-throughput methodology (hundreds of genes can be screened
on hundreds of tumors) with those of a high-resolution technology
(each core can be analyzed by visual inspection, thereby allowing
the identification of the cellular origin of the signal in a
heterogeneous tissue). We have previously extensively validated
the specificity and the dynamic range of detection of this method
(for instance, as compared to those obtainable with highly
quantitative methods, such as Q-PCR), in a number of large
screening projects [23–26]. The ISH/TMA screening led to the
identification of 22 DUBs that were dysregulated in human
cancers, for a total of 34 occurrences of dysregulation (Figure 1A).
Selected DUBs were subjected to further validation by analyzing
their expression in large cohorts of tumor samples (Figure 1A).
Analysis of alterations in DUB expression in human
cancers by ISH/TMA
We screened by ISH/TMA ,300 tumors, including carcino-
mas of the breast, colon-rectum, larynx, lung (non-small cell lung
carcinomas, NSCLCs), stomach, kidney and prostate, non-
Hodgkin’s lymphomas (NHLs) and melanomas (the composition
of the TMAs is described in Table S1). In addition, we screened
,260 normal samples from the same tissues (frequently, and
whenever possible, from the same patient, see Table S1; for NHL,
we used reactive lymph node tissue as the normal counterpart,
while for melanoma we used benign nevi). The 89 screened DUBs
included 55 USPs, 4 UCHs, 5 MJDs, 13 OTUs, and 12 JAMMs
(listed and described in Table S2).
Of the 89 analyzed transcripts, 33 (37%) could be detected (ISH
score.1) in at least one of the analyzed tissues (Table S3). The
remaining genes were either undetectable (40 genes) or barely (16
genes) detectable in the analyzed tissues, likely due to low mRNA
abundance. Of note, in all cases in which antisense probes yielded
positive signals, the corresponding sense probe, used as a negative
control, did not yield any appreciable signal (data not shown). The
complete set of results is shown in Table S2 and Table S3.
Twenty-two DUBs were dysregulated (67% of all detectable
genes and ,25% of all screened genes) in a statistically significant
manner (Figure 1B, and Tables S2 and S3) in at least one tumor
type (see Figure 2 for representative examples). Eleven other DUB
mRNAs (CYLD, USP2, USP4, USP7, USP15, USP18, USP21,
USP25, USP49, PRPF8, OTUB1) were expressed in various
tissues or tumors, but were not significantly dysregulated (see
Table S3). Overall, there were 34 instances in which a specific
DUB was significantly dysregulated in a given tumor type, with
respect to the normal counterpart; of these, 22 (65%) were
upregulations, while 12 (35%) were downregulations (Figure 1B).
Strikingly, 9 upregulations occurred in larynx carcinomas, while 6
downregulations occurred in NHLs. Breast carcinoma was the
only tumor type in which we observed both up- and down-
regulations. No DUBs were significantly dysregulated in prostate
carcinomas, and only one was found in kidney (UCHL1,
downregulated), suggesting that different tumor types display
different levels of alteration of the deubiquitination machinery.
Finally, while 15 DUBs were found to be significantly dysregulated
in only one type of cancer, 7 (UCHL1, USP9X, USP11, USP10,
USP22, COPS5 and COPS6) displayed multiple alterations in two
or more tumor types (Figure 1B).
With therapeutic implications in mind, the most interesting
DUBs were those expressed at low or undetectable levels in most
normal tissues, while being upregulated in at least one tumor type.
In these cases, the dysregulated DUBs frequently displayed
overexpression only in a fraction of tumor samples, suggesting
that their levels might also be useful for patient stratification for
eligibility for anti-DUB therapy. For instance, UCHL1 in lung
carcinomas (likewise in larynx carcinomas) was strongly expressed
in 7 out of 25 tumor samples (28%), while it was completely
undetectable in the normal counterpart. Moreover, USP31 was
highly expressed in 8 out of 27 larynx carcinomas (30%), and only
in 2 out of 31 normal tissues, where its expression was restricted to
the proliferative basal layer (data not shown).
Extended analysis of selected DUBs in large cohorts of
tumor patients
To further investigate the alterations of DUBs in human
cancers, we analyzed the expression of selected DUBs in large
cohorts of human tumors. We concentrated on NSCLCs and
melanomas as examples of tumors harboring frequent upregula-
tion of DUBs, and gastric carcinomas as examples of tumors
displaying downregulation of DUBs.
In NSCLCs, four DUBs were significantly overexpressed:
JOSD1, COPS5 UCHL1 and USP9X (Figure 1B). JOSD1 is still
totally uncharacterized at the functional level, and was therefore
not further investigated. COPS5, on the other hand, has been
extensively characterized in tumors, including NSCLCs (see
Discussion), rendering its additional characterization less neces-
sary. We concentrated, therefore, on the analysis of UCHL1 and
USP9X by ISH/TMA on a case collection of 420 consecutive
NSCLC samples (described in Table S4). We observed that
UCHL1 expression directly correlated (P,0.001) with tumor
grade, gender and Ki67 expression, while USP9X expression
directly correlated with Ki67 expression (P,0.001; Table 1).
Furthermore, both DUBs were more frequently expressed in lung
squamous cell carcinomas (SSC), compared with adenocarcinomas
(AC).
DUBs in Cancer
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In the initial screening of melanoma samples, five genes
(USP10, USP11, USP22, USP48 and COPS5) were significantly
overexpressed, compared with benign nevi. We performed an in-
depth analysis on four of them (COPS5 was not analyzed for the
reasons mentioned in the previous paragraph) on a large
melanoma case collection (described in Table S5). The expression
of three out of four analyzed genes (USP10, USP11, USP22) was
significantly higher in metastatic melanoma compared with benign
nevi and primitive tumors (Table 2), suggesting that their
expression is associated with a more aggressive and invasive
phenotype. This conclusion is supported by the significant
correlation observed between DUB expression and clinico-
pathological parameters indicative of advanced disease (Table 2),
including the Breslow index (for USP10 and USP22), the Clark
index (for USP22, USP11 displayed a borderline correlation), the
presence of ulceration (for USP10 and USP22), and the number of
mitotic cells (for USP10 and USP22, USP11 displayed a
borderline correlation). USP48 expression did not correlate with
any clinico-pathological parameters since low levels of transcript
were detected in almost all tumor samples (.95%, data not
shown). Thus, in a significant number of melanoma cases, DUB
expression correlated with some of the strongest known prognostic
factors, projecting their usefulness in prognostic models.
Finally, we measured the expression of USP1 on a gastric
cancer ‘‘progression’’ TMA containing normal gastric epithelia,
intestinal metaplasia, dysplasia, primary carcinomas and metasta-
Figure 1. Dysregulation of DUBs in human cancers. A. A scheme of the study design is shown. Left (boxed in black), strategy and results of the
ISH/TMA screening; right (boxed in red), strategy of the extended analyses (details are in the main text). All DUBs expressed in human tissues (90,
according to [8]) were analyzed; however, the sequence of the JAMM family member ENSG00000198817 was retired from the ENSEMBL database;
moreover the genomic context to which this putative transcript was assigned (chr2:58,390,463–58,391,299) (see Table S1 in [8]) now corresponds to
the FANCL gene that is an E3 ligase. B. Dysregulation of DUBs in human cancers. The mean levels of expression in various human tumors (T) and
matched normal tissues (N) are shown by a semi-quantitative color code, reflecting the mean ISH scores. Actual scores (and P values) are listed in
Table S3. Asterisks mark statistically significant (P#.05) differences (black asterisks, upregulation; red asterisks, downregulation). ** Benign nevi were
used as normal tissue counterparts for melanomas. *** For non-Hodgkin’s lymphomas (NHLs), we used reactive lymph node tissues as the normal
counterpart.
doi:10.1371/journal.pone.0015891.g001
DUBs in Cancer
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ses (Table S6). We observed that the expression of USP1 was lost
in the transition from the normal to the metaplastic state (Table 3,
see also Figure 1B and Figure S1). All abnormal and neoplastic
gastric tissues were negative for USP1 expression, possibly
indicating that this event correlates with the initial steps of
transformation of the gastric mucosa.
Figure 2. Representative examples of in situ hybridization-tissue microarray data. Examples of the data summarized in Figure 1B are
shown for normal and tumor tissues. In each pair, the upper panel is a bright field (for morphological evaluation) and the lower panel is a dark field
(transcripts appear as bright dots). Magnifications of selected areas are also shown below each individual core.
doi:10.1371/journal.pone.0015891.g002
DUBs in Cancer
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Discussion
Herein, we provide the first atlas of alterations of DUB
expression in human cancers. The complete repertoire of DUBs
encoded by the human genome was analyzed in nine types of
cancer, which included the four most frequent cancers (lung,
prostate, breast, colon-rectum), and which account for,two thirds
of all cancer cases and cancer deaths in the western world.
Twenty-two DUBs were found to be significantly dysregulated
in at least one type of cancer. In seven cases (UCHL1, USP9X,
USP11, USP10, USP22, COPS5 and COPS6), dysregulation was
observed in more than one tumor type. Considering that only 33
of the 89 screened DUBs displayed quantifiable ISH signals, it
appears that these enzymes are frequently altered in human
cancers. Obviously, dysregulation in tumors does not constitute per
se evidence for a causal involvement in cancer. In our extended
analyses, however, we observed an association between the
expression of selected DUBs and relevant clinico-pathalogical
parameters, in some cases indicative of aggressive disease. These
data support the notion that at least some of the detected
dysregulations might have a role in tumorigenesis. In addition,
some of the characterized DUBs might provide useful markers for
diagnostic/prognostic evaluation (e.g., USP10, USP11 and USP22
in melanoma), or might represent therapeutic targets (e.g., DUBs
that are highly expressed in tumors, but absent in normal tissues),
regardless of their exact role in tumorigenesis.
Several of the dysregulated DUBs identified here have already
been shown to be involved in cancer (for recent reviews see
[18,19]). For instance, COPS5 is overexpressed in several tumor
types [27,28], and its overexpression is associated with short
disease-free and overall survival in lung cancer [29,30]. Indeed,
COPS5 has been proposed as a target for anti-cancer drug
development [31].
USP9X expression has been shown to promote the self-renewal
of embryonic stem cell-derived neural progenitors, acting as a
neural stemness gene [32]; it promotes cell survival by stabilizing
MCL1, which is essential for the survival of stem and progenitor
cells of multiple lineages [33]. We found USP9X overexpressed in
lung cancer, suggesting that this event might be linked to the
expansion of the cancer stem cell compartment in this tumor: a
possibility that warrants further investigation.
Upregulation of UCHL1 expression was observed in bronchial
biopsies of smokers compared with non-smokers [34], and its
expression has been linked to disease outcome in lung cancer [35,36].
Moreover UCHL1 expression in cancer-associated fibroblasts of
colorectal cancer was found to be an independent prognostic factor
for overall and recurrence-free survival [37]. Finally, its overexpres-
sion strongly accelerated lymphomagenesis in Em-myc transgenic
mice through the enhancement of AKT signaling [38].
Another example is represented by USP22, which is part of a
small set of marker genes capable of predicting metastatic potential
and therapeutic outcome in human cancer [39,40]. USP22 is
overexpressed in colorectal cancer and its activation is associated
with tumor progression and therapy failure [41]. USP22 may exert
its oncogenic potential through the BMI-1 oncogene-driven
pathway signature by activating c-Myc-targeted genes, such as
cyclin D2 [41]. Notably treatment with USP22-specific siRNA and
aiRNA (asymmetric interfering RNA) inhibits the growth of
implanted bladder tumors in vivo [42], possibly through the
downregulation of Mdm2 and cyclin E, resulting in the
stabilization of p53 and p21 and ensuing cell cycle arrest [42].
In all these cases, our findings support the notion that these
DUBs play an important role in human cancer, and further pose
the question of which are the molecular mechanisms responsible
for their dysregulation. In addition, it will be of interest to test
whether genetic alterations directly affecting the genes for theses
enzymes can be evidenced in cancer.
Conversely, for many other DUBs (USP31, USP39, USP48,
PSMD14, USP1, PSMD7, STAMBP, USP16, USP24, COPS6,
EIF3S5 and JOSD1) our findings represent, to the best of our
knowledge, the first report of alterations in cancer. Two of these
DUBs, PSMD7 and PSDM14, are component of the proteasome,
and might therefore be of direct relevance to therapy, including
patient stratification, in light of the fact that the proteasome
inhibitor bortezomib has already been approved for the treatment
of multiple myeloma and mantle cell lymphoma [43], and that
additional clinical trials for the treatment of solid tumors and other
hematological malignancies are in progress [44]. In particular,
PSMD14 was identified as an important DUB of the 19S lid
complex of the proteasome [45]. Its activity is essential for
substrate deubiquitination during proteasomal degradation [46],
and may also play a role in the editing of polyubiquitinated
substrates as a mean to control degradation, possibly in a
proteasomal-independent fashion [47,48]. Moreover PSMD14
has been shown to deubiquitinate the transcription factor JUN; its
overexpression contributes to JUN stabilization and activation of
Table 1. Analysis of selected DUB expression in a large case
collection of NSCLCs.
UCHL1 USP9X
Parameter Group NEG POS P NEG POS P
Age ,65 80 59 121 23
$65 113 81 0.911 161 48 0.137
Nodal
Status
Neg. 95 68 131 44
Pos. 98 72 0.912 151 27 0.024
Ki67 Neg. 94 34 122 14
Pos. 78 101 ,0.001 133 55 ,0.001
Grade G1 26 3 26 4
G2 84 44 114 22
G3 78 93 ,0.001 138 44 0.133
p53 Neg. 99 58 129 32
Pos. 82 79 0.032 133 37 0.687
pT 1–2 156 104 217 55
3–4 37 36 0.180 65 16 1.000
Stage 1 77 52 102 35
2-3-4 116 88 0.649 180 36 0.056
Histotype AC 123 56 170 23
SCC 70 84 ,0.001 112 48 ,0.001
Gender Female 55 17 60 20
Male 138 123 ,0.001 222 51 0.266
Correlation between DUB expression and clinico-pathological parameters in
NSCLCs. Expression was measured by ISH-TMA (Negative (NEG), ISH score#1;
Positive (POS), ISH score.1). P-values were measured by Fisher’s exact test
(Pearson Chi Square was used when three or more parameters were
considered). Note that the number of scored cases is lower than the total
number of cases since: i) cores that gave a low b-actin signal in the control
hybridization (see Methods) were excluded from further consideration; ii) in
some cases, individual cores detached from the slides during the manipulations;
iii) complete clinical information was not available for all patients. Histotypes:
AC, adenocarcinoma; SCC, squamous cell carcinoma. In tumor tissues, the ISH
signals were associated with the tumor cell component and not with the
adjacent or infiltrating stroma.
doi:10.1371/journal.pone.0015891.t001
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its downstream target genes [49], thereby conferring moderate
resistance to chemotherapeutic drugs [50]. It will be therefore of
interest to evaluate whether the possible contribution of PSMD14
to human cancer occurs through proteosomal-dependent or –
independent functions.
The possible relevance of DUB dysregulation to human cancers
is best appreciated in the framework of available knowledge on
their role in biochemical circuitries involved in cellular regulation.
While a comprehensive discussion of the known functions of all the
dysregulated DUBs identified in this study will be impossible here
(see however Table S2 and [8,18,19] for recent reviews of the
biochemical functions of DUBs implicated in cancer), we would
like to briefly highlight some of the functional characteristics of the
DUBs that were extensively validated in the present study
(USP9X, UCHL1, USP1, USP10, USP11, and USP22). These
DUBs are involved in the regulation of cellular functions relevant
to cancer, including signal transduction pathways, apoptosis,
transcription, regulation of chromatin, and DNA repair processes.
USP9X, UCHL1 and USP11 have been implicated in the
regulation of signal transduction pathways. USP9X interacts with b-
Table 2. Analysis of selected DUB expression in melanoma progression.
USP10 USP11 USP22
Parameter Group NEG POS P NEG POS P NEG POS P
Type Nevi 20 0 25 0 21 0
Melanoma 104 8 121 10 99 25
Met. Mel. 34 19 ,0.001 35 18 ,0.001 27 25 ,0.001
Histotype NM 13 2 14 1 9 6
SSM 90 5 0.243 105 7 0.950 89 16 0.031
pT 1 21 0 28 0 22 0
2–4 47 8 0.097 52 7 0.091 38 22 ,0.001
Nodal status Neg. 23 5 32 4 17 17
Pos. 8 3 0.663 9 2 0.614 8 3 0.297
Regression No 74 4 85 5 67 20
Yes 29 3 0.413 34 3 0.691 30 3 0.119
Ulceration No 75 1 88 5 77 8
Yes 28 6 0.003 32 3 0.683 21 15 ,0.001
TIL No 67 3 77 4 64 12
Yes 36 5 0.143 42 5 0.287 33 12 0.163
Mitotic Count 0–1 42 0 49 0 44 2
2–6 36 2 37 4 28 10
.6 17 6 ,0.001 20 4 0.022 13 11 ,0.001
Breslow 0–1 56 0 67 2 62 0
2–3 29 2 31 4 23 11
3+ 18 6 ,0.001 22 3 0.149 13 13 ,0.001
Clark 1–2 30 0 42 0 37 0
3–5 72 8 0.104 77 9 0.029 60 24 ,0.001
Age ,65 75 26 83 35 69 29
$65 5 3 0.436 8 1 0.444 14 7 0.795
Gender Female 42 4 50 4 43 10
Male 62 4 0.715 71 5 0.855 56 14 0.875
Correlation between DUB expression and clinico-pathological parameters in melanomas. Expression was measured by ISH-TMA (Negative (NEG), ISH score#1; Positive
(POS), ISH score.1). P-values were measured as in Table 1. Note that the number of scored cases is lower than the total number of cases (see Table 1). Histotypes: NM,
nodular melanoma; SSM, superficial spreading melanoma. TIL: tumor-infiltrating lymphocytes. In all melanomas (including metastatic ones), the ISH signals were
associated with the tumor cell component and not with the adjacent or infiltrating stroma.
doi:10.1371/journal.pone.0015891.t002
Table 3. Analysis of USP1 expression in the progression of
gastric cancer.
Analyzed
Samples Positive Negative % Positive
Normal Mucosa 18 17 1 92
Intestinal
Metaplasia
14 0 14 0
Displasia 9 0 9 0
Primary tumor 28 0 28 0
Metastasis 13 0 13 0
USP1 expression was measured in normal, metaplastic, dysplastic and
neoplastic gastric tissues by ISH-TMA (Negative, ISH score#1; Positive, ISH
score.1). In the normal gastric mucosa the ISH signals were observed
throughout the thickness of the epithelial component, irrespectively to the type
of glands analyzed.
doi:10.1371/journal.pone.0015891.t003
DUBs in Cancer
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catenin in vitro and in vivo [51,52] and probably mediates its
deubiquitination, thereby increasing its half-life [51]. UCHL1
might be involved in the same pathway, since it forms endogenous
complexes with b-catenin, stabilizes it, and upregulates b-catenin/
TCF-dependent transcription [53]. Moreover, UCHL1 and b-
catenin can positively regulate each other [53]. The effects of
USP9X, and possibly of UCHL1, might therefore mimic activation
of the Wnt signaling pathway, which is known to cause b-catenin
stabilization and translocation into the nucleus, and has been
implicated in a variety of human cancers (for reviews see [54–57]).
USP9X might also act as a regulator of the TGF-b pathway,
another signaling circuitry of great relevance to cancer (reviewed in
[58]), as witnessed by the fact that loss of USP9X abolishes multiple
TGF-b gene responses [59]. Mechanistically, this might depend on
the ability of USP9X to activate SMAD4 by removing its
monoubiquitination, which in turn prevents the formation of the
effector SMAD2/SMAD4 complex [59]. Finally, USP11 is involved
in the regulation of the NF-kB signaling pathway [60,61].
There is evidence that USP9X and USP10 might be involved in
cell survival pathways. USP9X deubiquitinates and stabilizes
MCL-1, a pro-survival BCL2 family member [33], whose
overexpression is associated with several neoplastic conditions
[62–64]. USP10, on the other hand, has been shown to be
responsible for the deubiquitination of p53 in the cytoplasm,
allowing its stabilization and re-entry into the nucleus. Indeed,
downregulation of USP10 decreases p53 stability and increases
cancer cell proliferation [65], thus projecting a role as a tumor
suppressor. Interestingly, however, USP10 can also act like an
oncogene, by promoting cancer cell proliferation in cells harboring
mutant p53 [65], an event possibly connected with the fact that
some p53 mutants display aberrant gain-of-function activity that is
stabilized through deubiquitination by USP10.
There is also evidence for an involvement of USP22 and USP1
in a series of nuclear events, including organization of chromatin
and telomeres, and DNA repair, the subversion of which might
lead to cellular transformation. USP22 is necessary for appropriate
progression through the cell cycle, and it is a component of the
human SAGA complex, a transcriptional co-activator complex.
Within SAGA, USP22 catalyzes the deubiquitination of histones
2A and 2B, thereby, counteracting heterochromatin silencing [66].
Moreover, it deubiquitinates TRF1, a component of the telomere
nucleoprotein complex that functions as an inhibitor of telomerase
[67], thereby affecting TRF1 stability and telomere elongation
[68]. Finally, USP1 deubiquitinates and inactivates two compo-
nents of DNA repair mechanisms: FANCD2 (a component of the
Fanconi Anemia pathway) [4,69] and PCNA [70]. Ubiquitination
of FANCD2 and PCNA is important for their roles in DNA repair
[71,72], suggesting that subversion of USP1 in human cancers
might impinge on transformation events through alterations of
DNA repair pathways.
Finally, the interactome of human DUBs has been recently
reported [73], which links DUBs to diverse cellular processes,
including protein turnover, transcription, RNA processing, DNA
damage, and endoplasmic reticulum-associated degradation. The
DUB interactome provides the foundations, onto which additional
layers of complexity can now be added, such as the atlas of DUB
alterations in cancer reported herein, to build a reference map for
the pleiotropic involvement of DUBs in cellular homeostasis.
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Identification and selection of DUBs, cDNA templates and
probe preparation
We used the Pfam (Pfam 22.0, July 2007) [74], the InterPro
(InterPro 16.0, August 2007, http://www.ebi.ac.uk/interpro/),
and the SMART databases to retrieve all proteins containing one
of the five Ub-protease domains. After removing overlapping
sequences, we identified 55 USPs, 4 UCHs, 5 MJDs, 13 OTUs,
and 12 JAMMs, which represented the 89 genes screened on
TMAs (Table S2).
EST clones were obtained from our in-house Unigene clone
collection, or from IMAGENES (http://www.imagenes.de/). All
clones were sequence verified. BLAST searches were performed to
identify the most specific ,300 bp regions, shared by the highest
number of transcript variants for each individual gene, and
riboprobes were synthesized as described previously [23].
Tissue samples
For the large-scale screening study, formalin fixed and paraffin
embedded specimens were provided by the Pathology Depart-
ments of Ospedale Maggiore (Novara), Presidio Ospedaliero
(Vimercate), and Ospedale Sacco (Milan). Samples were arrayed
onto different TMAs (Table S1), prepared essentially as previously
described [23,25,75]. Each sample was arrayed in duplicate (also
for the TMAs engineered for the extended analyses, see below).
Details of the TMA engineering are in Table S1.
For the extended analyses of representative DUBs, we used
three different cohorts:
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1. Lung cancer cohort. We designed lung-specific TMAs
composed of 420 NSCLCs (244 adenocarcinomas and 176
squamous cell carcinomas), provided by the European Institute
of Oncology (Milan). Clinical and pathological characteristics
are reported in Table S4.
2. Melanoma cohort. We designed a melanoma-progression
TMA composed of 32 benign lesions (nevi), 138 primary
melanomas, and 62 metastatic melanomas provided by the
Pathology Departments of Ospedale S. Paolo (Milan) and by
the European Institute of Oncology (Milan). Clinical and
pathological characteristics are in Table S5.
3. Gastric cancer cohort. This cohort was arrayed onto a gastric
cancer progression TMA, which contained 31 primary gastric
carcinomas (8 early and 23 advanced) provided by Ospedale S.
Paolo (Milan) and Fondazione IRCCS Ospedale Maggiore
Policlinico, Mangiagalli e Regina Elena (Milan). Non-neoplas-
tic specimens (13 dysplasias, 23 intestinal metaplasias and 23
normal mucosae) and 13 lymph node metastases from the same
patients were also arrayed. Clinical and pathological charac-
teristics are reported in Table S6.
In situ hybridization (ISH)
ISH was performed as previously described [23]. All TMAs
were first analyzed for the expression of the housekeeping gene b-
actin, to check the mRNA quality of the samples. Cases showing
absent or low b-actin signals were excluded from the analyses (data
not shown). In addition, in all cases where antisense probes yielded
positive signals (33 genes), the corresponding sense probe, used as
a negative control, did not yield any appreciable signal. Gene
expression levels were evaluated by counting the number of grains
per cell and were expressed on a semi-quantitative scale (ISH
score): 0 (no staining), 1 (1–25 grains; weak staining), 2 (26–50
grains, moderate staining), and 3 (.50 grains, strong).
The mean ISH score was calculated when two (or more) cores
of the same sample were present. Mean ISH scores.1 were
considered as an unequivocal positive signal. Mean ISH scores
between 0 and 1 were considered as a negative signal. Note that
the number of scored cases, in some experiments, is lower than the
total number of arrayed cases. This is due to a number of reasons:
i) all cores that gave a low b-actin signal in the control
hybridization were excluded from further consideration; ii) in
some cases, individual cores detached from the slide during the
manipulations.
Statistical analysis
Dysregulation (up- or down-regulation) was evaluated by
assessing differences between the tumor and the normal groups
with the Fisher’s exact test and the Student’s t-test, and only if the
difference in the average scores between the two groups was .0.5.
Differences were judged as significant at confidence levels equal to
or greater than 95% (p#0.05; see Table S3). Analyses were
performed using JMP statistical software (SAS Institute, Inc., Cary,
NC). The association between clinico-pathological parameters of
the tumors and DUB expression in the melanoma and lung tumor
cohorts was evaluated using the Fisher’s exact test, or with the
Pearson chi-square test when three or more parameters were
evaluated at the same time.
Supporting Information
Figure S1 High resolution images of data presented in
Figure 2 of the main text. High magnifications of the TMA
core showing USP1 expression in normal gastric mucosa. Top,
hematoxylin/eosin staining; bottom, dark field. The boxed areas
highlight the presence of a region of intestinal metaplasia, within
the normal gastric mucosa, showing the absence of USP1.
(TIF)
Table S1 Four different multi-tissue TMAs (indicated as
TMA A–D) were prepared. For their engineering, two tumor
areas (diameter 0.6 mm) and two normal areas (0.6 mm, arrayed
whenever available) from each specimen were first identified on
haematoxylin-eosin stained sections, and subsequently removed
from the donor blocks and deposited on the recipient block using a
custom-built precision instrument (Tissue Arrayer-Beecher Instru-
ments, Sun Prairie, WI 53590, USA) coupled to a motorization kit
(MTABooster-Alphelys, Plaisir, France). We also engineered two
TMAs containing only normal tissues (normal TMAs 1 and 2), from
different donors. In this case, we deposited in duplicate larger cores
(diameter 1.5 mm) to allow for better characterization of the normal
tissue architecture. In each column, the number of cases deposited
on each TMA is reported (T, tumor; N, normal). * For non-
Hodgkin’s lymphoma (NHL), we used reactive lymph node tissues
as the normal counterpart. ** For melanomas, benign nevi were
used as the normal tissue counterpart. Different TMA combinations
were used for the screening. With reference to the 33 detectable
genes: USP49 and OTUB1 were hybridized only to TMA D and
Normal TMA-2; EIF3S5, PRPF8 and PSMD7 to TMAs C–D and
to Normal TMAs 1–2; STAMBP, COPS6 and EIF3S3 to TMAs
A–D and to Normal TMAs 1–2; all other 25 genes were hybridized
on TMAs A–C and to Normal TMA-1.
(DOC)
Table S2 List of screened DUBs identified by their
family name (UCH, USP, OTUBIAN, MACADO, JAMM),
symbol (HUGO nomenclature, used throughout this
paper), definition, aliases (if known), accession num-
bers (mRNA Acc ID, Prot Acc ID, and EST Acc/RZPD
clones ID), function (see below), and relevant referenc-
es. The column ‘‘TMA Expression’’ reports delectability in the
ISH/TMA procedure. Functions were derived by merging
information obtained from PubMed and the GeneCards Database
(http://bioinfo1.weizmann.ac.il/genecards/index.shtml). n.a.: not
available.
(DOC)
Table S3 Mean values of the data presented in Figure 1B
of the main text. The mean ISH score of replicate cores arrayed
in the TMAs was used to calculate the final ISH scores for each
tumor sample. Number of normal and tumor samples analyzed
(nuN and nuT respectively) and number of positive samples are
reported for each screened tissue. Mean gene expression was
calculated as indicated in the Methods and is reported separately
for tumor (Average T) and normal tissues (Average N). Statistical
significance between mean expression levels in T and N was
calculated as reported in the Methods and P-values are reported.
In tumor tissues, in all cases, the ISH signals of the over- or under-
expressed genes were associated with the tumor cell component
and not with the adjacent or infiltrating stroma. The same was
true for normal tissues.
(XLS)
Table S4 The clinical and pathological information for
the patients of the NSCLC cohort is reported. For some
patients not all information was available (No data). *For three
patients no follow-up was available.
(DOC)
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Table S5 The clinical and pathological information for
the patients of the melanoma cohort is shown. Clinical
parameters are reported only for the 138 primary melanomas. For
some patients not all information was available (No data).
Histotypes: NM, Nodular Melanoma; SSM, Superficial Spreading
Melanoma; TIL: Tumor-Infiltrating Lymphocytes.
(DOC)
Table S6 The clinical and pathological information for
the patients of the gastric cancer cohort is reported. For
some patients not all information was available (No data). Class:
EGC, early gastric cancer; AGC, advanced gastric cancer.
(DOC)
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